Publications

Spotlight Publication

Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

American Association for Cancer Research (AACR)

Apr 25
- Apr 30, 2025
Neoadjuvant botensilimab plus balstilimab in MMR proficient and deficient early-stage cancers: first results of the pan-cancer NEOASIS study
Chalabi et al.

Filter by

Balstilimab (PD-1 Antagonist)

European Society for Medical Oncology (ESMO)

Oct 19
- Oct 23, 2018
Phase 1/2 Study of CTLA-4 Inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in Patients With Advanced/Refractory Solid Tumors, With Expansion Into Second-Line Cervical Cancer and Solid Tumors.
Coward, et al.
Balstilimab (PD-1 Antagonist)

European Society for Medical Oncology (ESMO)

Oct 19
- Oct 23, 2018
Phase 1/2, Open-Label, Multiple Ascending Dose Trial of AGEN2034, an Anti–PD-1 Monoclonal Antibody, in Advanced Solid Malignancies: Results of Dose Escalation in Advanced Cancer and Expansion Cohorts in Subjects With Relapsed/Refractory Cervical Cancer.
Drescher, et al.
Balstilimab (PD-1 Antagonist)

Society for Immunotherapy of Cancer (SITC)

Nov 6
- Nov 10, 2019
Single-agent Activity of a Novel PD-1 Inhibitor, AGEN2034, in Recurrent Ovarian Cancer.
O’Malley, et al.
Balstilimab (PD-1 Antagonist)

European Society for Medical Oncology (ESMO) Virtual

Sep 19
- Sep 21, 2020
Balstilimab (anti-PD-1) Alone and in Combination with Zalifrelimab (anti-CTLA-4)for Recurrent/Metastatic (R/M) Cervical Cancer (CC) Preliminary Results of Two Independent Ph2 Trials .
O’Malley, et al.
Balstilimab (PD-1 Antagonist)

Oncogene

Jan 26, 2021
Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor.
Grossman, et al.
Balstilimab (PD-1 Antagonist)

SGO 2021 Virtual Annual Meetings on Women’s Cancer Abstracts

Mar 19
- Mar 22, 2021
RaPiDS (GOG-3028): A Randomized Phase II Studyof Balstilimab (AGEN2034) as Monotherapy or in Combination with Zalifrelimab (AGEN1884) in Second-Line Cervical Cancer.
O’Malley, et al.
Balstilimab (PD-1 Antagonist)

American Society of Clinical Oncology (ASCO)

Jun 3
- Jun 7, 2021
Differentiated Activity Profile for the PD-1 Inhibitor Balstilimab.
C.Joyce, et al.
Balstilimab (PD-1 Antagonist)

Gynecologic Oncology

Aug 25, 2021
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
O’Malley, et al.
Balstilimab (PD-1 Antagonist)

European Society for Medical Oncology (ESMO) Virtual

Sep 16
- Sep 21, 2021
Balstilimab Alone or in Combination with Zalifrelimab as Second-line Treatment for Patients with Previously Treated Recurrent/metastatic Cervical Cancer: a Randomized, Placebo-Controlled Phase II Trial (RaPiDS/GOG-3028).
Randall, et al.
Balstilimab (PD-1 Antagonist)

European Society for Medical Oncology (ESMO) Virtual

Sep 16
- Sep 21, 2021
Balstilimab (anti-PD-1) in Combination with Zalifrelimab (anti-CTLA-4): Final Results from a Phase 2 Study in Patients (pts) with Recurrent/metastatic (R/M) Cervical Cancer (CC).
O’Malley, et al.
AGEN2373 (CD137 Agonist)

Society for Immunotherapy of Cancer (SITC)

Nov 7
- Nov 11, 2018
AGEN2373 is a Conditionally-Active Agonist Antibody Targeting the Co-Stimulatory Receptor CD137 for the Treatment of Human Malignancies.
Galand, et al.
AGEN2373 (CD137 Agonist)

Society for Immunotherapy of Cancer (SITC)

Nov 9
- Nov 14, 2020
AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects.
Galand, et al.